New Therapies for Reducing Low-Density Lipoprotein Cholesterol

作者：Stein Evan A^*; Raal Frederick J

来源：Endocrinology and Metabolism Clinics of North America, 2014, 43(4): 1007-+.

DOI：10.1016/j.ecl.2014.08.008

• LDL cholesterol
• Apo B antisense
• MTP inhibitors
• PCSK9 inhibitors

Although the past 4 decades have been the most productive in transitioning from an low-density lipoprotein cholesterol (LDL-C) hypothesis to demonstration of clinical benefit, cardiovascular disease remains a major cause of mortality and morbidity. It is fortunate that most of the effective lipid-lowering drugs, the statins, have become generic and inexpensive. However, there remains a large unmet medical need for new and effective agents that are also well tolerated and safe, especially for patients unable to either tolerate statins or achieve optimal LDL-C on current therapies. It is likely that the agents discussed in this review will fill that need.

• 出版日期2014-12